Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q20311716> ?p ?o }
Showing triples 1 to 26 of
26
with 100 triples per page.
- Q20311716 subject Q18703802.
- Q20311716 subject Q7110135.
- Q20311716 abstract "Axovant Sciences, Ltd. is a Bermuda-based public company which develops pharmaceutical drugs for dementia. Axovant intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral components of dementia and related neurological disorders.The company's initial public offering in 2015 was thought at the time to be the highest grossing ever in the biotechnology industry. Axovant trades on the New York Stock Exchange under the symbol "AXON".The founder of Axovant is Vivek Ramaswamy, a former hedge-fund manager. Ramaswamy had previously founded Roivant Sciences in May 2014, then created Axovant as a spin-off company from Roivant in October. As of 2015, Roivant retained a 75% ownership stake in Axovant.Axovant's Chief Development Officer is Dr. Lawrence Friedhoff, who previously led the development and approval of Aricept (donepezil), the most widely used drug for the treatment of Alzheimer's disease.".
- Q20311716 wikiPageExternalLink 2015-06-11.
- Q20311716 wikiPageWikiLink Q105611.
- Q20311716 wikiPageWikiLink Q11081.
- Q20311716 wikiPageWikiLink Q1186164.
- Q20311716 wikiPageWikiLink Q12140.
- Q20311716 wikiPageWikiLink Q1331905.
- Q20311716 wikiPageWikiLink Q13677.
- Q20311716 wikiPageWikiLink Q185142.
- Q20311716 wikiPageWikiLink Q18703802.
- Q20311716 wikiPageWikiLink Q2103933.
- Q20311716 wikiPageWikiLink Q212322.
- Q20311716 wikiPageWikiLink Q22277838.
- Q20311716 wikiPageWikiLink Q23635.
- Q20311716 wikiPageWikiLink Q415081.
- Q20311716 wikiPageWikiLink Q4788901.
- Q20311716 wikiPageWikiLink Q6990276.
- Q20311716 wikiPageWikiLink Q7108.
- Q20311716 wikiPageWikiLink Q7110135.
- Q20311716 wikiPageWikiLink Q83030.
- Q20311716 wikiPageWikiLink Q855449.
- Q20311716 wikiPageWikiLink Q891723.
- Q20311716 comment "Axovant Sciences, Ltd. is a Bermuda-based public company which develops pharmaceutical drugs for dementia. Axovant intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral components of dementia and related neurological disorders.The company's initial public offering in 2015 was thought at the time to be the highest grossing ever in the biotechnology industry.".
- Q20311716 label "Axovant Sciences".